A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

NCT02741791 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment Resistant Major Depressive Disorder

Interventions

DRUG: AXS-05
DRUG: Bupropion

Sponsor

Axsome Therapeutics, Inc.